Reed Johnson Selected Research

Amantadine (Aman)

1/2022	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
6/2021	Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia.
1/2020	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
1/2019	Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
1/2019	Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.
1/2019	Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
3/2018	Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.
1/2018	Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
1/2018	Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
1/2017	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Reed Johnson Research Topics

Disease

10	Dyskinesias (Dyskinesia) 06/2021 - 01/2017
10	Parkinson Disease (Parkinson's Disease) 06/2021 - 01/2017
2	Infections 05/2014 - 01/2013
1	Multiple Sclerosis 01/2022
1	Hallucinations (Hallucination) 01/2020
1	Constipation 01/2020
1	Edema (Dropsy) 01/2020
1	Urinary Tract Infections (Urinary Tract Infection) 01/2020
1	Coronavirus Infections 01/2020
1	Disease Progression 01/2019
1	Movement Disorders (Movement Disorder) 03/2018

Drug/Important Bio-Agent (IBA)

11	Amantadine (Aman)FDA LinkGeneric 01/2022 - 01/2017
7	Levodopa (L Dopa)FDA LinkGeneric 06/2021 - 01/2017
1	Pharmaceutical PreparationsIBA 01/2020
1	AerosolsIBA 01/2020
1	VaccinesIBA 05/2014
1	Chemokine ReceptorsIBA 01/2013
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2013
1	InterferonsIBA 01/2013

Therapy/Procedure

3	Therapeutics 01/2020 - 05/2014
1	Activities of Daily Living (ADL) 01/2019
1	Drug Therapy (Chemotherapy) 01/2018
1	Duration of Therapy 01/2018